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Summary 
Polyomavirus (PyV) infection of SCID mice, which lack functional T  and B  cells, leads to a le- 
thal acute myeloproliferative disease (AMD) and to high levels of virus replication in several or- 
gans by two wk after infection. This is in contrast to infection ofT cell-deficient athymic nude 
mice, which are resistant to acute PyV-induced disease and poorly replicate the virus in their 
organs. This major difference in the virus load and in the outcome of PyV infection between 
SCID and nude mice suggested that an efficient, T  cell-independent antiviral mechanism oper- 
ates in T  cell-deficient, PyV-infected mice. To investigate this possibility, mice with different 
genetically engineered  T  and/or B  cell deficiencies and SCID mice adoptively reconstituted 
with B and/or T  cells were infected with PyV. The results indicated that the presence of B cells 
in the absence of T  cells protected mice from the AMD, and this was accompanied by a major 
reduction  of PyV  in  all  organs  tested.  Sera  from  PyV-infected T  cell  receptor  (TCIK) e~[3 
knockout or TCR ot[3 ~/8 knockout mice contained IgG2a antibodies to PyV. Sera or purified 
immunoglobulin fractions from PyV-infected TCR oq3 knockout mice protected SCID mice 
from the PyV-induced AMD. To our knowledge, this is the first report of an effective T  cell- 
independent  antibody response clearing a virus and changing the  outcome of infection from 
100% mortality to 100% survival. 
V 
irus-specific  T  cells  usually  play  a  major role  in  the 
process of recovery from acute virus infections (1). Af- 
ter an early phase of the infection, when nonspecific factors 
such as NK cells contribute to decreasing the virus load (2), 
MHC-restricted cytotoxic T  cells locate and destroy virus- 
infected  target cells.  T  cells  also secrete  cytokines,  which 
further impair virus replication and participate in several as- 
pects of the immune response (3).  For the generation of a 
high-affinity  antibody  response  and  for  efficient  isotype 
switching  from  IgM  to  IgG  and  IgA production,  T  cell 
help is believed to be essential  (4--4).  In some virus infec- 
tions,  such  as  vesicular  stomatitis  virus  (VSV)  1,  reovirus, 
and Sindbis virus, humoral immunity in the presence of T 
cells  can play a  significant role in  the  control of infection 
(7-9).  Of interest is  that athymic nude mice can clear in- 
tracerebral  Sindbis  virus  infection  similarly  to  immuno- 
competent mice, suggesting that a T  cell-independent im- 
mune response may restrict the replication of this pathogen 
(10,  11).  Nude mice, however, are not completely free of 
T  cells, and a role for T  cells or T  cell-dependent antibod- 
ies could  not be  excluded  in  those  experiments.  Efficient 
1Abbreviations used in  this paper." AMD, acute mydoproliferative  disease; 
LCMV, lymphocytic  choriomeningitis virus; PyV, polyomavirus;  VSV, 
vesicular stomatis  virus. 
control of an acute virus infection by antibodies produced 
in the absence ofT cells has therefore not been shown. 
Recent developments in immunology, using mice with 
targeted disruption  (knockout)  of certain genes, show that 
there are many redundancies  in the immune system. Mice 
defective in gene products shown to be important for con- 
trol  of infections  often can  clear viruses  or parasites with 
unexpected  efficiency.  For example, in  mice  defective in 
CD8 + T  cells,  virus infections known to be controlled by 
CD8 + CTL were  cleared by compensating CD4 + T  cells 
(12,  13).  A potent anti-lymphocytic choriomeningitis virus 
(LCMV)  T  cell response and VSV clearance in IFN-~/re- 
ceptor knockout  mice  (14);  detectable  CTL  responses  to 
LCMV infection in IL-2 knockout mice (15),  and the con- 
trol ofleishmaniasis in CD4 knockout mice (16) are further 
examples.  This  rePort  shows  that  although  T  cells  in  the 
absence of B cells can provide full protection against polyo- 
mavirus (PyV) infection in mice, B  cells can also clear PyV 
in a completely T  cell-independent fashion, supporting the 
view that the immune system has components with over- 
lapping functions, and providing the first unambiguous ex- 
ample of a protective T  cell-independent antiviral antibody 
response. 
PyV  induces  a  lethal  acute  myeloproliferative  disease 
(AMD)  in  SCID  mice that  lack functional  T  and B  cells 
(17).  This observation is surprising since hematological dis- 
orders are not part of the disease spectrum caused by PyV 
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mice (18,  19). Moreover, the AMD in SCID mice is asso- 
ciated with high levels of PyV replication on day  14  after 
infection in all major organs tested, whereas in nude mice 
virus replication cannot be detected in most organs at this 
time  (17,  20,  21).  This  enhanced virus replication and vi- 
rus-induced pathology in  SCID  versus nude  mice suggest 
that an alternative mechanism of PyV clearance is operating 
in mice deficient in T  cells. Here we demonstrate that PyV 
infection induces virus-specific IgM and IgG production by 
B  cells in the absence ofT  cell (and NK cell) help, and that 
this  antibody response  can  clear PyV  and  protect  T  cell- 
deficient mice from the acute lethal myeloproliferative dis- 
ease caused by the virus. 
Materials  and Methods 
Mice and Virus Infection.  C57BL/6JSz  SCID  mice,  129  TCR 
c~13"y8-/- mice, which had a targeted disruption in their TCR 
13 and 8 genes (22) and therefore lacked functional cq3 and "y8 T 
cells,  129￿  Ix-/-  mice, which  had  no  functional B 
cells (23),  129XC57BL/6 and BALB/c mice were obtained from 
The Jackson Laboratory (Bar Harbor, ME). 129￿  TCR 
c~13-/- mice, which had a targeted disruption of the TCR c~ or 
13 gene (24), and therefore had no functional o~13 T  cells, had been 
backcrossed three-to-four times to C57BL/6. The TCtL o~13-/- 
(initially from Drs. P. Mombaerts and S. Tonegawa, Massachu- 
setts Institute of Technology, Cambridge, MA) and C.B17 SCID 
mice were bred in the Department of Animal Medicine of the 
University of Massachusetts  Medical Center, and were housed in 
microisolator cages in this facility. Mice to be infected were inoc- 
ulated intraperitoneaily with 2  ￿  105-2 ￿  106 50% tissue culture 
infectious  dose  (TCID50)  of PyV  strain  A2,  provided  by  Dr. 
Michele M. Fluck (Michigan State University, East Lansing, MI). 
In Vivo NK or T Cell Depletion.  Mice with the C57BL/6  back- 
ground, which express the NKI.1  alloantigen, were depleted of 
NK  cells by i.p. injection with  20-100  IX1 of previously deter- 
mined  optimal  dilutions  of ammonium  sulfate  cuts  of ascites 
preparations of a  rnonoclonal antibody to  NKI.1  (25).  C.B17 
SCID mice and TCR ~13~/~-/- mice, which do not express the 
NKI.1 alloantigen, were depleted of NK cells by an i.p. injection 
of 10  IXl of antiserum  to  asialo  GM1  (Wako  Chemicals USA, 
Dallas,  TX).  The anti-NKl.1 or asialo GM1  injections were re- 
peated weekly. The effectiveness of NK cell depletion was tested 
by using splenocytes of the depleted mice in cytotoxicity assays 
with 51chromium-labeled conventional NK target cells (YAC-1) 
in vitro. 
CD4+  and CD8+  T  cells were depleted in vivo by i.p. injec- 
tion of 80  txl of an ascites preparation of a rat anti-mouse CD4 
rnonoclonal antibody (clone GK1.5 [26]), and of 150 Ixl of a  1:10 
dilution of an ascites preparation of a rat anti-mouse CD8 mono- 
clonal  antibody  (clone  2.43  [27]),  respectively. The  injections 
were  repeated every 6-7  d.  The  effectiveness of depletion was 
tested by FACS  |  (Becton Dickinson Co., Mountain View, CA) 
staining of peripheral blood leukocytes of killed mice, and these 
samples were found to  be 98-99%  free of CD4 + and  CD8 + T 
cells. 
Adoptive  Transfer Experiments.  Spleens  harvested  from  mice 
were ground between the frosted ends of glass microscope slides; 
the resulting cell suspension was  filtered through  a  nylon mesh 
and  treated  with  0.83%  NH4C1  to  remove  erythrocytes.  Cells 
prepared from two-to-three spleens (with or without in vitro T 
cell depletion) were  suspended in  650  ILl PBS;  200  IXl of this 
spleen cell suspension per mouse  was  given intravenously into 
C.B17  SCID mice. The adoptive transfer of cells was performed 
1 d before the infection of the mice intraperitoneally with 2  ￿ 
10  s TCIDs0 units of PyV strain A2. 
In  Vitro T Cell Depletion.  Depletion  of CD4 +  and  CD8 +  T 
cells in spleen cell preparations in vitro was performed by treating 
the cells with rat anti-mouse Thy-1 monoclonal antibody (clone 
J1J.10 rat ascites preparation [28]; l:50 dilution, 150 IXl/107 cells) 
on ice for 45 rain, washing them twice with PBS, adding 25  IXl/ 
107 cells of guinea pig serum as a complement source, and then 
incubating the cells for 10 min on ice and for 50 min at 37~  Fi- 
nally, the cells were washed twice and suspended in medium. 
Southern Blots.  DNA was prepared from frozen organs (liver, 
lung, kidney, and spleen) following published protocols (29). 2-10 
Ixg of undigested DNA or DNA cut with EcoRI, which cuts the 
PyV genome once, was subjected to electrophoresis in 0.8% aga- 
rose gels, and transferred to nitrocellulose paper by vacuum blot- 
ting (30), or to nylon transfer membrane (Magna Charge; Micron 
Separations Inc., Westboro, MA) by capillary transfer.  The DNA 
blot was then baked, prehybridized, hybridized, washed, and ex- 
posed to autoradiography as described (31). PyV strain A2 cloned 
in pAT153 plasmid was kindly provided by Dr. Michele M. Fluck, 
and it was 32p-labeled by random priming for use as a hybridiza- 
tion probe. 
Immunofluorescent Staining.  NIH  3T3  clone  A31  cells  were 
seeded  on  microscope  glass  coverslips  and  infected  with  PyV 
strain A2.  On  day 3  after infection,  the  cells  on  the  coverslips 
were fixed for 10 rain with a  1 : 1 mixture of ethanol and ethyl- 
ether,  followed by  20  rain  in  95%  ethanol.  Staining was  per- 
formed in a humid chamber for 35 rain at room temperature with 
dilutions  of sera  from  PvY-infected immunocompetent  or cx13 
knockout mice or of normal (uninfected) mouse serum. The cov- 
erslips were subsequently rinsed with PBS and incubated for 35 
rain  with  FITC-labeled antibodies specific for  mouse  IgM  (IX 
chain),  IgG  (~/  chain)  (Vector  Laboratories,  Inc.,  Burlingame, 
CA), IgG1, IgG2a, IgG2b, and IgG3 (Zymed Laboratories, Inc., 
San  Francisco,  CA).  The  coverslips  were  rinsed  with  PBS, 
mounted on microscope slides with 90% glycerol/10% PBS, and 
viewed by fluorescence microscopy. 
Purification of IgG from  PyV-infected oefl Knockout Mouse  Serum. 
A protein A-Sepharose CL-4B (Pharmacia Biotech, Piscataway, NJ) 
column was prepared according to the manufacturer's instructions 
and washed with  0.1  M  Tris-HC1, pH  8.0  (binding buffer).  A 
0.5-ml sample of pooled serum harvested on day 14 after PyV in- 
fection of o~13 knockout mice was  mixed with 50  p,1 I  M  Tris- 
HC1,  pH 8.0,  loaded on the column, and washed with binding 
buffer  (10￿  column  volume).  The  IgG fraction was  eluted by 
0.1 M  citric acid, pH 3.0.  To preserve the activity of acid-labile 
IgG, each collected fraction (0.5 ml) was neutralized by the addi- 
tion of 50 IXl 1 M  Tris-HC1, pH 9.0.  The protein content of the 
fractions was determined by an  OD  280  reading, and the PyV- 
specific IgG content by indirect fluorescent staining. 
Results 
Outcome  of PyV Infection  in  Mice Deficient  in  T  and~or  B 
Cells.  We have shown  that SCID mice developed a fatal 
AMD after infection with PyV. The incidence of the AMID 
(100%) and the survival time of  the SCID mice (14~16 d) was 
not influenced by the  genetic background  of the  mice  or 
404  T Cell-independent Antibody Response to Polyoma Virus Table 1.  PyVoinduced  Disease in Immunodeficient Mice 
Mice  No. of mice  Depletion (in vivo)  Killed* (day)  Disease 
C.B17 SCID  15  -  13.6 +- 0.5'  AMD 
C57BL/6 SCID  22  -  13.9 +  1.3  AMD 
C.B17 SCID  5  ctAGM1  14.2 +  0.8  AMD 
C57BL/6 SCID  22  oLNKI.1  13.9 +  1.3  AMD 
TCR ~t13 -/-  3  -  28(1)~  GI 
69(1)  GI 
87(1)  Healthy 
TCR ctl3-/-  4  otNKl.1  67(1)  GI 
87(3)  Healthy 
TCR ctl3~/8- / -  4  -  14(2)  Healthy 
42(2)  Healthy 
TCK ot13~/8-/-  5  otAGM1  14(2)  Healthy 
42(3)  Healthy 
I~- / -  3  -  110 (3)  Healthy 
~-/-  3  otCD4/ctCD8  15.7 +  0.6  AMD 
Ix  + / +  3  -  110 (3)  Healthy 
Ix  + / +  3  ctCD4/txCD8  110 (3)  Healthy 
*  Mice were killed healthy or moribund on the indicated day. Moribund mice had ruffled fur, pale ear color, and hunched posture, and would be ex- 
pected to die within 24 h according to previous experiments. 
r  deviation. 
~No. of  mice. 
GI, gastrointestinal disease, 
by the presence or absence of NK cells  (17).  The fact that 
this pathology was very different from the tumor induction 
described  in nude  mice indicated  that B  cells  and/or  ex- 
trathymically developing T  cells  might have an important 
role in PyV pathogenesis.  To address this question, we in- 
fected  mice  having  various  T  and/or  B  cell  deficiencies 
with PyV (Table  1). 
Mice that had a targeted disruption in the TClk ot or 13 
gene (ct13 knockout mice)  (24)  survived the acute phase of 
PyV  infection  and  did  not  show  any  symptoms  of the 
AMD up until 3 mo after infection. Depletion of the TClk 
or13 knockout mice of NK cells in vivo by anti-NKl.1  anti- 
bodies  did  not  influence  this  outcome.  Mice  deficient  in 
both 0tl3 and ~/g T  cells (22) also survived, regardless of the 
presence or absence of NK cells.  Two of three ct13 knock- 
out mice and one of four NK-depleted ct13 knockout mice 
had to be killed between day 28 and 69 after infection, be- 
cause the animals had gastrointestinal obstruction or serious 
wasting  associated  with  diarrhea.  These  symptoms  were 
consistent  with  an  ulcerative  cohtishke  pathology  that  is 
known to affect this mutant mouse strain  (32).  Therefore, 
we consider the death of these animals not PyV related. 
Mice deficient in functional B cells due to a targeted dis- 
ruption of the Ig Ix chain gene (Ix-/-)  (23) were also re- 
sistant to the PyV-induced acute myeloproliferation. How- 
ever,  when  these  Ix-/-  mice  were  depleted  in  vivo  of 
CD4 + and CD8 + T  ceils by combined injections with anti- 
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CD4 and anti-CD8 antibodies,  the animals (three of three) 
died  of AMD  by  day  16,  similarly  to  SCID  mice.  Mice 
with functional B  cells from the same genetic background 
did not show any sign of PyV-induced disease,  even when 
depleted  of CD4 +  and  CD8 +  T  cells.  These  experiments 
indicate that although T  cells  can provide resistance against 
PyV infection, even in the absence of B  cells,  if functional 
CD4 + and CD8 + T  cells are not present, B cells can mount 
an effective antiviral response as a second line of defense. 
Prevention of PyV-induced AMD by Adoptive  Transfer of B 
Cells into SCID Mice.  To  further  investigate  the  role  of 
different cell populations of the immune system in the re- 
sistance  to  PyV  infection,  adoptive  transfer  experiments 
were performed (Table 2). Spleen cells were prepared from 
uninfected,  immunocompetent  BALB/c  mice.  This  cell 
population  was used  directly for adoptive  transfer,  or was 
first depleted ofT cells in vitro by lysing the cells with anti- 
Thy-1  antibody and  complement.  The  success  of the  de- 
pletion  was  monitored  by  FACS  |  staining.  Splenocytes 
from ot13 T  cell knockout mice, B  cell knockout mice, and 
B  cell knockout mice after T  cell depletion were also used 
for adoptive transfer into SCID mice.  Adoptive transfer of 
the  total  spleen  cell  population  (T  and B  ceils)  protected 
SCID mice not only from AMD, but from later tumor in- 
duction as well. All mice receiving B cells (Thy-l-depleted 
splenocytes, or spleen  cells from ct13 knockout mice) were 
protected  from the  AMD,  but  in  a  fraction  of these  ani- Table 2.  Protection  of C. B I 7 SCID Mice  from Py V-induced Acute Disease by Adoptive  Cell Transfer 
No. of  Source of cells  Depletion  Cell No. 
mice  transferred  (in vitro)  given  Day Killed*  Disease 
Exp. 1  2  C.B17 spleen  ccThy-1  2.5 )<  107  96  Tumor (1)* 
Healthy (1) 
Exp. 2  3  C.B17 spleen  -  108  105  Healthy (3) 
3  C.B17 spleen  ~Thy-I  5  X  107  90  Hind leg 
Paralyzed (1) 
Healthy (2) 
3  TCP,, ot[3-/-  -  ND -~  68  Tumors (2) 
68  Healthy (1) 
Exp. 3  4  Ix-/-  spleen  otThy-I  1.1  X  10  ('  13.2  AMD (4) 
4  b~+/+ spleen  otThy-1  3  ￿  107  82  Tumors (2) 
Healthy (2) 
*Mice were killed healthy or moribund on the indicated day. 
*No. of mice. 
~Cell number was not determined, cells prepared from three cq3 knockout mouse spleens were injected into three recipient SCID mice. 
mals,  PyV  infection  induced  multiple  mammary  tumors. 
This  finding is  consistent  with  published  data  showing  a 
high  frequency  of mammary  tumors  in  female  BALB/c 
nude mice (21).  Four out of four SCID mice that received 
adoptive transfer of T  cell-depleted splenocytes from B  cell 
knockout  mice  died by day  14  with  symptoms  of AMD, 
indicating the essential role orB cells in protection when T 
cells were absent. 
Py V Replication  in SCID Mice Reconstituted  with B or B and 
T  Cells.  Whereas in immunocompetent or nude mice the 
PyV replication is not detectable in most major organs by 2 
wk after infection, in SCID mice high levels of virus repli- 
cation have been observed at this time in all organs tested 
(17,  20).  We asked whether the protection of SCID  mice 
from the AMD  by B  cells was associated with a major de- 
crease in the amount of the virus in different organs. SCID 
mice, SCID mice adoptively transferred with B  cells (Thy- 
1-depleted splenocytes) or with B  and T  cells (undepleted 
spleen cells) were infected with PyV and killed at days 3, 7, 
and  14  after  infection.  The  presence  of viral  genome  in 
DNA samples prepared from spleen, kidney, liver, and lung 
tissues of the animals was analyzed by Southern blots, using 
cloned,  32p-labeled PyV  A2  genome  as  the  hybridization 
probe. At day 3, all three groups of mice had viral signal in 
the spleen (Fig. 1 A). At this time DNA samples from other 
organs  (kidney, lung, and liver) did not show the presence 
of viral genome,  even  after  a  long  exposure  of the  blots 
(kidney and lung not shown).  At day 7,  strong viral bands 
could be observed in all four organs in SCID mice, a find- 
ing consistent with our previous results (17). In SCID mice 
adoptively transferred with B  cells alone, or with B  and T 
cells, very little or no virus-specific DNA  was detected in 
any of the organs tested. Even in the spleen the viral signal, 
which could be observed at day 3,  was largely diminished 
by day 7  (Fig.  1  /3). At day 14, whereas PyV could be de- 
tected in all four organs in SCID mice, the virus signal was 
absent from SCID mice receiving B  cells or T  and B  cells 
(Fig. 1  C  and Fig. 2/3).  The fact that we could not observe 
significant differences in the efficiency of PyV clearance in 
the spleen, kidneys, liver, or lung by B  cells alone or by T 
and B  cells together at  day 7  and  14  after infections indi- 
Figure 1.  Effect  of adoptive transfer of B and T cells on PyV replica- 
tion in spleen and liver of C.B17 SCID mice. Southern blots of DNA 
samples (5 I-~g)  prepared from organs of SCID mice, SCID mice reconsti- 
tuted  with  Thy-l-depleted BALB/c spleen cells (SCID+B  cells), and 
SCID  mice  reconstituted with  spleen cells of BALB/c  mice  (SCID+ 
T+B cells)  taken at different times after infection. The blots were probed 
with 32p-labeled  cloned PyV genome. (A) Uncut DNA of spleens (lanes 
1-3) and livers (lanes 4-6) at day 4 after infection. SCID mice (lanes 1 
and 4), SCID+B cells (lanes 2 and 5), and SCID+T+B cells (lanes 3 and 
6). (/3) Day 7 postinfection EcoRI-cut DNA from spleens (lanes 1-3) and 
livers (lanes 4-6)  of SCID mice (lanes 1 and 4), SCID+B cells (lanes 2 
and  5),  SCID+T+B  cells (lanes 3  and  6).  (C)  Day  14  postinfection 
EcoRI-cut DNA from spleens (lanes 1-3) and livers (lanes 4-6) of SCID 
mice (lanes 1 and 4), SCID+B cells (lanes 2 and 5), SCID+T+B ceils 
(lanes 3 and 6). 
406  T Cell-independent Antibody Response to Polyoma Virus Figure 2.  Transfer of  serum from PyV-infected 
ct[3 knockout mice into C.B17 SCID mice causes 
major delay in PyV replication. (A) PyV-infected 
SCID mice treated with serum of PyV-infected 
tx[3 knockout mice; Southern blot of DNA sam- 
ples (1  p,g/lane) from spleen (lanes 1, 5,  9, and 
15), kidney (2, 6, 10, and 16), liver (3, 7,  11, and 
17), and lung (4, 8,  12, and 18). Lanes 1-4: day 4 
after infection, lanes 5-8: day 13, lanes 9-13 and 
15-I8: day 32. Lane I4:0.1  ng pAT153-PyV A2 
plasmid DNA.  (B)  PyV-infected SCID mouse. 
Day  13  after infection. Lane 1:  spleen, lane 2: 
kidney, lane 3:  hver, and lane 4:  lung. Probe: 
32p-labeled, cloned PyV A2 genome. 
cates that B  cells could control PyV rephcation in these or- 
gans in the absence ofT cells. 
Protection  Against  AMD  Is Mediated  by  Serum.  We tested 
whether  serum  from  PyV-infected  ct[3 knockout  mice 
could transfer protection to SCID mice against PyV-induced 
AMD.  ot[3 knockout  mice  and  C57BL/6  mice  were  in- 
fected with  PyV;  7  d  after  infection,  the  mice  were  bled 
and serum was harvested.  C.B17 SCID mice were then in- 
jected  with  the  sera  1  d  before  PyV infection.  Sera  from 
normal,  uninfected  mice  were  used  as  negative  controls. 
Sera  from PyV-infected  C57BL/6  mice  or ot[3 knockout 
mice prolonged the  survival of the  SCID mice,  regardless 
of the  route  of injection  (i.p.  or i.v.)  (Table  3).  Sera from 
uninfected  mice  did not have  any effect on survival.  The 
mice that received  "PyV-immune" sera died between  day 
37  and  48  after  infection  with  the  pathological  signs  of 
AMD. This indicates that a single injection of serum could 
not completely prevent but could delay the lethal outcome 
by 3-4 wk;  the  same  3-4-wk delay in the onset of AMD 
was observed when serum harvested at day 14 after PyV in- 
fection ofot[3 knockout mice was used (Table 4). The pro- 
longed survival was accompanied by a delay in the kinetics 
of virus rephcation (Fig. 2).  In SClD mice treated with day 
7 serum of PyV-infected ot[3 T  cell-deficient mice, no viral 
DNA could be detected by Southern blots at day 4  and 14 
after  PyV  infection,  although  by  this  time  in  untreated 
SCID  mice,  high  levels  of PyV  replication  could  be  ob- 
served in  all  organs  tested.  However,  by day 32,  the  PyV 
genome  became  readily  detectable  in  samples  of spleen, 
kidney,  hver,  and  lung  DNA  from the  PyV-immune  se- 
rum-treated SCID mice (data from two individual mice are 
shown in Fig. 2). 
Serum of Py V-infected  T  Cell-deficient Mice Contains  Virus- 
specific IgM and IgG.  To determine whether serum derived 
from PyV-infected cx[3 knockout mice at day 14 after infec- 
tion contains PyV-specific IgM or IgG antibodies,  indirect 
immunofluorescent  staining  experiments  were  performed. 
3T3 cells infected with PyV for 3 d were reacted with a  1:20 
dilution of the serum, followed by staining with FITC-con- 
jugated murine  IX chain- or murine y  chain-specific second 
antibody.  Bright  nuclear  fluorescent  staining  of the  PyV- 
infected cells  could be  observed with  the y  chain~specific 
reagent (Fig. 3 A). This staining was specific, because PyV- 
infected cells exposed to non-PyV-immune serum and the 
anti-y-FITC antibody  exhibited  only diffuse,  cytoplasmic 
background fluorescence  (Fig.  3  B.).  Using PyV-immune 
ot13 knockout serum with  FITC-antimurine  Ix antibody,  a 
virus-specific nuclear fluorescent  signal was  also  observed, 
indicating  that  T  cell-deficient  mice  mount  virus-specific 
IgM  and  IgG  responses  against  PyV.  Immunofluorescent 
Table 3.  Effect  of Serum  Transfer on the Survival  Time of Py V-infected C. B 17 SCID Mice 
No. of  Source of serum  Route of  Killed* 
mice  transferred  Serum dose  injection  (day)  Disease 
Exp. 1  3  Uninfected C57BL  500 ml  i.p.  13.3  --- 0.6*  AMD 
3  PyV-infected C57BL~  500 ml  i.p.  45 (3)11  AMD 
Exp. 2  1  Uninfected C57BL  100 +  250 Ixl  i.v.  +  i.p.  15 (1)  AMD 
2  PyV-infected TCR otl3 -/-~  100 +  250 Ixl  i.v.  +  i.p.  40 (2)  AMD 
Exp. 3  2  Uninfected C57BL  200 txl  i.v.  14 (2)  AMD 
2  PyV-infected C57BL~  200 Ixl  i.v.  37 (2)  AMD 
2  PyV-infected TCR Ix[3-/-~  200 txl  i.v.  48 (2)  AMD 
*Mice were killed moribund on the indicated day. Moribund mice had milled fur, pale ear color, and hunched posture, and would be expected to 
die within 24 h according to our previous experiments. 
*Standard deviation. 
~Serum was harvested at day 7 after infection. 
IINumber of  mice. 
407  Tsuda and Welsh Table 4.  Ig Fractions of PyV-infected c~ Knockout Mouse Serum Prolong the Survival of PyV-infected C.B17 SCID Mice 
No. of  Mice*  Serum given (i.v.)  Volume  Titer*  Time of deaths 
/xl  d 
Exp. 1  2  None  --  --  16,17 
2  Naive ix[3 knockout serum  150  ND  15,18 
2  Naive normal mouse serum  100  ND  16,17 
2  PyV-infected, ot[3 knockout serumEI  100  ND  39 +￿82 
2  Peak I**  200  < 1:20  20,21 
2  Peak I**  450  <1:20'*  21,21 
2  Peak llg~  200  1:20  19,21 
Exp. 2  2  None  --  --  13,13 
2  PBS  100  --  15,17 
2  PyV-infected, ot[3 knockout serumll  100  1:800  39,48 
2  IgG fr.41111  100  1:200  33,41 
2  IgG fr.51111  150  1:80  36,40 
*Mice were injected with l0  s TCIDs0 of PyV strain A2 i.p. on the day ofi.v, serum injections. 
*Titer defined as the highest dilution of serum resulting in positive immunofluorescence  of PyV-infected 3T3  cells with an IgG-specific FITC- 
labeled second antibody. 
SMice were killed moribund on the indicated day (see footnote to Tables 1 and 3). 
ItSemm was harvested on day 14 after infection. 
￿82  mouse died on day 39, the other was killed with no symptoms. 
**Peak I chromatography fraction contained both IgM and IgG. 
**Peak I fraction showed positive IgG-specific fluroescence undiluted, but in 1:20 dilution was negative. 
~Peak II chromatography fraction contained only IgG. 
ImlgG-containing fractions of ot[3 knockout mouse serum harvested  14 d after PyV infection were obtained by chromatography on a protein 
A-Sepharose column (see Materials and Methods). 
staining  of PyV-infected  3T3  cells  with  serum  of PyV- 
infected  ot[3 knockout  mice  (1:20  dilution)  and  FITC- 
labeled second antibodies specific for subclasses of IgG re- 
vealed that the serum of PyV-infected ot[3 knockout mice 
contained  predominantly  IgG2a,  as  IgGl-,  IgG2b-,  and 
IgG3-specific staining was not detectable. However, bright 
nuclear  fluorescence  was  observed  with  the  anti-IgG2a- 
FITC  antibody.  Sera  from  PyV-infected,  NK-depleted 
oL[3~/8 knockout  mice  harvested  2  wk  after infection  also 
contained levels of IgG2a comparable to those of the PyV- 
infected cx[3 knockout mouse serum. Staining with a  1:100 
dilution of this sera and  IgG2a-specific FITC-labeled anti- 
bodies resulted in bright nuclear fluorescence of PyV-infected 
cells (not shown). 
To  test whether purified IgM or IgG fractions of PyV- 
infected ot[3 knockout mice can protect SCID mice against 
the acute PyV-induced disease, the serum was fractionated 
by  chromatography  on  a  Sephacryl 300  (Pharmacia  Bio- 
tech,  Uppsala,  Sweden)  column.  The  first  protein  peak 
eluted from  the  column  was  enriched  for  IgM,  but  con- 
tained  IgG  as  well.  The  second  protein  peak  contained 
IgG, but no detectable IgM. SCID mice injected with 200 lxl 
of either fraction survived PyV infection significantly longer 
than SCID mice treated with sera of naive knockout mice 
before infection (Table 4, Exp.  1).  In a second experiment, 
high titer antiviral IgG was purified by protein A-Sepharose 
chromatography from the serum of 0t[3 knockout mice har- 
vested on  day  14  after infection.  C.B17  SCID  mice were 
injected  intravenously  with  unfractionated  PyV-infected 
ci[3 knockout serum  (titer  1:800) and the peak IgG fractions 
fr.4 and ft.5  (titer  1:200  and  1:80,  respectively)  (Table  4, 
Exp. 2). Whereas all the mice without serum or IgG treat- 
ment died by day 17 (mean survival time 14.5  +  1.9), mice 
that received the purified IgG fractions from PyV-infected 
ot[3 knockout mouse serum survived 19-27  d  longer.  Fur- 
thermore, this survival time was very similar to that of mice 
injected  with  unfractionated  PyV-infected  cl[3 knockout 
mouse serum, indicating that IgG produced in the absence 
of T  cells expressing ot[3 TCR  provides protection against 
the lethal outcome of PyV infection (Table 4). 
Discussion 
We show here that B  cells in the absence of T  cells pro- 
tect mice from PyV-induced lethal AMD.  This protection 
is mediated by the induction of PyV-specific IgM and IgG 
antibodies, predominantly IgG2a, produced without any T 
cell help. These  antibodies then dear PyV in different or- 
gans of the PyV-infected mice. To  our knowledge,  this is 
the first example of a  completely T  ceLl-independent anti- 
body response effectively reducing virus load ("clearance") 
408  T Cell-independent Antibody Response to Polyoma Virus and thereby dramatically changing the  outcome of a virus 
infection (from 100% lethality by day 16 to 100% survival). 
It is well known  that virus-specific antibodies  can pre- 
vent  infection  or  reinfection  by  neutralization  (33),  and 
several studies have indicated that antibodies are also  capa- 
ble  of mediating virus clearance in vivo. Examples of this 
are reovirus and Sindbis virus clearance in the central ner- 
vous system of neonatal or SCID mice by the injection of 
monoclonal antibodies (8, 34),  or influenza virus clearance 
by transfer of monoclonal antibodies into SCID mice (35). 
However, the generation of an efficient, high-affinity anti- 
body response and the switching from IgM to IgG or IgA 
production usually requires T  cell help (4,  5).  It is very in- 
teresting therefore,  that PyV is an inducer  of a  protective 
antibody  response  in  T  cell-deficient  mice.  In  PyV- 
infected SCID mice, the virus replicates to high levels, and 
the high level of virus antigens might be an important re- 
quirement for triggering T  cell-independent antibody pro- 
duction.  This is  also  suggested by a  recent publication by 
Freer et al.  (36),  which reported induction of VSV-specific 
IgG in nude mice. In that system, the T  cell dependence of 
both IgG and, to a lesser degree, IgN1, seemed to be depen- 
dent  on  the  antigen  dose,  and  only at  very high  antigen 
levels of UV-inactivated VSV was an  "inefficient but sig- 
nificant" switch to IgG synthesis observed. However, since 
nude mice are not completely free ofT cells, the possibility 
of helper factors produced by the remaining T  cells was not 
excluded in those experiments. 
It is interesting to speculate which factors might contrib- 
ute to the efficient switch from IgM to lgG production in 
the absence of any T  cell help (and even in the absence of 
NK cells) in the case of PyV infection. One factor in over- 
coming the lack of usual helper functions might be a char- 
acteristic  feature  of the  antigen.  The  major capsid  glyco- 
protein PyV, VP1, is repeated periodically 360 times (in 72 
pentamers)  in the virion capsid structure  (37,  38).  T  cell- 
independent antigens typically consist of multiple repeating 
epitopes that allow for extensive cross-linking of the  anti- 
gen receptor on the  B  cell surface.  Most T  cell-indepen- 
dent  antigens  are  polysaccharides,  but  polymeric  protein 
structures with repetitive epitopes, such as bacterial flagellin, 
can be T  cell-independent antigens as well (39, 40). There- 
fore,  the  structural  periodicity  of the  PyV  virion  capsids 
might be responsible, at least in part, for the ability to trig- 
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Figure 3.  Serum  from PyV-infected 
etl3 knockout mice contains PyV-spe- 
cific IgG. Staining of PyV-infected 
cells with (A) 1:20 dilution of serum 
from PyV-infected  etl3 knockout mice 
and FITC-labeled  antibody  specific  for 
mouse IgG "y chain. Strong nuclear 
fluorescence of PyV-infected cells in- 
dicates the  presence of PyV-specific 
IgG in the serum. (B)  1:20 dilution of 
serum  from uninfected  mice and 
FITC-labeled mouse IgG  ~/  chain- 
specific antibody. Only weak cytoplas- 
mic background staining can be ob- 
served. 
ger  T  cell-independent  antibody  responses.  This  idea  is 
supported by a report by Bachmann et al.  (41),  which de- 
scribes that transgenic  mice tolerant to nonrepetitive VSV 
glycoprotein  antigen  produced  antibodies  in  response  to 
the  highly  organized,  repetitive form of the  same antigen 
represented by formalin-inactivated virions. Therefore, the 
organization and density of antigenic  epitopes had an im- 
portant  role  in  determining  B  cell  induction.  However, 
since  many viruses have capsids with  similar  (icosahedral) 
repetitive structures, it is surprising that T  cell-independent 
antibody  responses  influencing  the  pathogenesis  of other 
virus infections have not been reported so far. The newly 
available mouse strains with  complete and selective T  cell 
deficiencies will be useful for determining how widespread 
this phenomenon is. Other factors in PyV-infected T  cell- 
deficient  mice,  such  as  the  production  of cytokines,  may 
also contribute to the induction of a strong T  cell-indepen- 
dent antibody response. 
Because  the  serum  from  PyV-infected  0tl3 knockout 
mice  has  some  neutralizing  activity in  vitro  (preliminary 
data, not shown), neutralization of PyV would be an obvi- 
ous mechanism of action of the antiviral antibodies. How- 
ever,  the  protective  effects  of antibodies  in  vivo  do  not 
necessarily correlate with their in vitro neutralizing abilities 
(42--44).  Both  neutralizing and nonneutralizing  antibodies 
can clear Sindbis virus in the infected central nervous sys- 
tem. In this case,  viral protein synthesis and virus assembly 
are  inhibited  by the  antibodies,  which bind  to  the  mem- 
brane  of the  virus-infected cells  (8).  In LCMV  infection, 
reduction of viral titers in tissues  is mediated by some, but 
not all neutrahzing antibodies. It is interesting to note that 
antibodies  with  IgG2a isotype  are  the  best  at  protecting 
against LCMV (43),  and that this isotype was shown to be a 
major component in the sera ofPyV-infected, T  cell-deficient 
mice. IgG2a is known to be predominantly produced in re- 
sponse to virus infections in general, and to PyV infection 
in particular, in immunocompetent mice (45).  It is surpris- 
ing,  however, that  this happens  even in  the  absence of T 
cells after PyV infection. 
In summary, our results show that PyV can behave as a T 
cell-independent antigen and provide the first unambigous 
example we know of a virus inducing a physiologically rel- 
evant, T  cell-independent antibody response that can con- 
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